In addition to basic research, Academica Sinica takes a leadership role in launching new initiatives in applied areas to meet a broad spectrum of social, medical and technological needs in Taiwan. Among its twenty-four research institutes and seven research centers are the Institute of Cellular and Organismic Biology, Institute of Biological Chemistry, Institute of Molecular Biology, Institute of Biomedical Sciences, Agricultural Biotechnology Research Center and the Genomics Research Center.

• Internal fixation of cells and organisms and uses thereof
• Compositions and Methods of Detection of Protein S-nitrosylation and Oxidation : PAC-switch method

The Development Center for Biotechnology(DCB) was founded in 1984 by Taiwan's Ministry of Economic Affairs, tasked with establishing the biotechnology industry in Taiwan. We strive to act as the industry’s partner, coordinating resources among government, academia and private companies. DCB remains a key force in building and upgrading Taiwan’s biomedical infrastructure, developing key technologies, and growing Taiwan’s professional workforce.

Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end, DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.

• Antibody-drug conjugates against cancer
• AXL Inhibitor as Anticancer Drug
• Hedgehog inhibitor as an anti-cancer agent
• Development of Tissue Specific Activated Antibody for Central Nervous System (CNS) Related Diseases
• High yield CHO production system
• Development of Anti-Mesothelin x CD3 BsAb for Mesothelin+ Cancer Therapy
• Tri-mannosyl Antibody: A Versatile Payload ADC Platform
• Development of Therapeutic Antibodies for Multiple-Drug Resistant Bacteria

Industrial Technology Research Institute (ITRI) is the leading nonprofit R&D organization engaging in applied research and technical services, aiming to innovate a better future. ITRI’s Biomedical Technology and Device Research Laboratories (BDL) works to bring about a future of health and happiness. At ITRI BDL, we focus on five core areas of research including botanical drugs, targeted drug and delivery technology, regeneration medicine, bio-IT and diagnostics and precision medicine. We have access to cutting-edge technologies, and provide technology transfer, licensing and other industry services. We would like to extend a hearty welcome to domestic and overseas businesses to file their applications for technology transfer or licensing, prototyping, or other industry services. ISO 13485, GMP, EU/FDA certified.

• Novel Lymphatic Delivery System for Cancer Metastasis
• Novel Functional Excipient for Development and Application of Insoluble Drug

The National Health Research Institutes (NHRI) was formally established in 1996 in Taiwan as a government-supported non-profit research organization with the purpose to promote and develop medical and health-related research in order to enhance social welfare for the people. As the only public research institute to focus entirely on human health and a think tank for the Ministry of Health and Welfare in Taiwan, the NHRI’s mission is to (a) advance biomedical sciences, (b) promote population and individual health, (c) forge biotechnology and pharmaceutical development, and (d) train and cultivate biomedical researchers. Since December 2004, the NHRI has relocated to its state-of-the-art main campus at Zhunan, which is close to the High-Tech cluster near Hsinchu Area, Taiwan. Currently, the NHRI, as a whole, comprises a community of more than 1,500 employees, including 130+ Principal Investigators, 170+ post-doctoral fellows, 750+ research assistants and 350+ supporting staff.

• AI-based mosquito trap
• A novel antibody against A possessing diagnostic and therapeutic potentials for Alzheimer’s disease
• DBPR114: an IND Approved Multi-targeted Kinase Inhibitor for Anticancer
• DBPR117: A Precision Medicine (mAb) Targeting RSPO3/Wnt-Mediated Tumorigenesis
• DBPR211: A Peripheral CB1 Antagonist An IND Approved First-in-Class Drug Candidate for T2DM
• DBPR215: Development of Stem Cell Mobilizers in Cell-Based Therapy
• DBPR807: A CXCR4-Targeted Antagonist
• BPR6K471: A Novel Aurora Kinase Inhibitor Targeting SCLC with MYC Amplification
• Genome Data Bank and Cancer Precision Medicine of Hepatocarcinoma (HCC) and Upper Tract Urothelial Carcinoma (UTUC)
• A Novel Small Molecule Drug Conjugate (SMDC) with Positive Feedback Encoded Ability on Tumor Site Apoptosis
• Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
• An Anti-Obesity Nanotechnology to Modulate Oil Absorption
• Targeted antigen delivery system
• MAP4K3 is a therapeutic target for cancer and IL-17A-mediated autoimmune disease

National Applied Research Laboratories (NARLabs) is a Taiwan government funded and non-profit organization. There are four main missions for NARLabs: establishing research and development platforms, supporting academic research, promoting frontier science and technology and fostering high-tech manpower.

For the innovation ecosystem, NARLabs will serve as a platform to align upstream and downstream segments along the R&D continuum, which will be one of the crucial aspects in Taiwan’s S&T transformation process. In this connection, the pressing task for the NARLabs is to augment the “translation” function and maximize its roles in elected projects of various fields with potentials for success. For example, the establishment of platforms of next generation smart electronics and experimental biological materials is to elevate the development potentials in Taiwan’s information and communication technology and bio-technology industries. Nonetheless, the related connection and integration shall proceed with the formulation of complementary measures and implementation of performance management so to meet the future needs in developing the country’s innovative R&D programs and economic system.

The R&D platform established by NARLabs carries the mission of creating social benefits and values. In a time when individual technologies can no longer meet future needs of society and industry in a fast-changing economic context, we have to take advantage of the established research capacity as a platform to collaborate with Taiwan’s outstanding multidisciplinary research teams in fostering various R&D initiatives that are forward-looking and challenging as well as of social value.

The NARLabs consists of:
National Laboratory Animal Center (NLAC)
National Center for Research on Earthquake Engineering (NCREE)
National Space Organization (NSPO)
National Center for High-performance Computing (NCHC)
Taiwan Semiconductor Research Institute (TSRI)
Instrument Technology Policy Research and Information Center (ITRC)
Science & Technology Policy Research and Information Center (STPI)
Taiwan Ocean Research Institute (TORI)

• MiiL – Bio Image Labeling Tool vvViewer – interactive VR App.

The Medical and Pharmaceutical Industry Technology and Development Center (PDC) was established by the government to execute the resolution of the 4th National Science and Technology Conference in 1991. The Center expanded its service scope towards building a communication platform for the integration of resources from industry, government, academia and research institutes to effectively improve overall technology levels of the medical and pharmaceutical industry. The ultimate mission is to cultivate key technology platform， upgrading the industry and internationalization.

• PDC-TacroBCR®
• Botanical Drug Development Platform Technology

The Council of Agriculture officially established the Agricultural Technology Research Institute (ATRI) in 2014 with the aim of turning agricultural innovation into entrepreneurship through technology business incubation. ATRI is a platform to connect the research institutes and industrial companies, in order to create a niche for farmers, companies, and value stakeholders, as well as promoting agriculture transformation and globalization. The mission of turning agricultural techno-innovation into techno-entrepreneurship with international compatibilities shall comply with the new agricultural policy and highlight Taiwan’s agriculture in the global market.

• Preclinical Testing Services of Pig
• SPF Pig Tissue Supply

The ambition of the ABBA is to nurture the first Taiwan Unicorn Enterprise in the healthcare field by integrating smart medical service, minimal-invasive surgery, intelligent medical devices, and healthcare-life sciences-blockchain. With the joint efforts of international innovative intelligences and Capitalists, we are aiming to creating a magnetic platform for the entire Taiwan health industry. The ABBA is powered by the International Clinical Trial Center and the diversified calibers of research engine reside in the China Medical University and Asia University. We are providing members service of bridging the R&D and manpower needs for Cell/Immune therapy, Precision Medicine, biophamaceutics, AI-based healthcare management, smart medical devices, and healthcare blockchain. ABBA vision to create the interests margin by powered biomedical products, international investment, and linking global Innovation and entrepreneurship. ABBA should expedite to fulfill the thirsty in the expanding market health industry in Taiwan.

Center For Membrane Technology (CMT) is independently established as an R&D institute who focuses on membrane separation for both industrial and biomedical applications, under the name of Chung Yuan Christian University (CYCU) in Taiwan. The ongoing pioneering technology development is our "Zwitterionic Surface Modification" (ZWI-TECH), which is able to apply onto surfaces of different materials, in order to render a surface property called super-hydrophilicity, which turns into anti-biofouling surfaces. With a water contact angle reaching 0 degree, the modified surface becomes super-hydrophilic and biofouling (which starts with non-specific binding of proteins) is optimally prevented. This technology holds infinite possibilities over fields of application including but not limited to bio-processings, fermentations, medical implants, marines, cosmetics, blood treatment and so on.

Centered on the National Central University, NCU GLORIA focuses on advanced technology fields to facilitate industry-academia collaboration by linking NCU with the global market while providing industries with talents and scientific research services. The GLORIA Project, accelerates global industry-academia collaboration by combining NCU’s research capability with industry partners, alumni support, and resources from various industry alliances. NCU possesses biomedical-related technologies across multiple healthcare disciplines, specifically in the fields of preventive medicine, diagnostics & evaluation, innovative therapy, and rehabilitation & learning in various medical settings.

GLORIA at NCKU is forging and strengthening mutually beneficial relationships between the institution and corporations worldwide.

‧We offer tailored research from NCKU, along with partners in Taiwan and members of the global alliance, to spur opportunities for enterprises. ‧We offer members access to NCKU’s global network, including industry-academic resource centers in Southeast Asian Nations. ‧The NCKU alumni in North America can promote R&D achievements in New York and Silicon Valley across a broad spectrum of industries. ‧We give an enterprise’s employees the training they need to take on new challenges. ‧Our industry clusters enhance enterprise-to-enterprise communication and put promising ideas and R&D innovations on the fast track to the global market.

National Chung Hsing University (NCHU), the leading research university in central Taiwan, will celebrate its 100th anniversary in 2019. Our faculty and alumni are the industrial leaders of innovation and incubation in central Taiwan and focus their leaderships on research and technology in agriculture, biotechnology, veterinary medicine, artificial intelligence, precision machinery, renewable energy and materials, circular economy, and cultural and creative industry.

As a leading institution in the development of agriculture field, the NCHU has its core competency in New Agriculture, including sustainability and recycling economy. The College of Agriculture and Natural Resources, the College of Veterinary Medicine, and the College of Life Science at the NCHU have accumulated abundant R&D achievements, by increasing the added value of agriculture and incorporating with the Industry 4.0, to establish the future of New Agriculture. The Alliance has divided its focus and services into five areas: creating new businesses, matchmaking industry-university collaboration projects, technology transfer, recruiting Alliance members, and cultivation of international talents.

Southern Taiwan Gloria the largest scale of R&D platform in Taiwan. We provide talent acquisition, technology sourcing, Consulting services, Cross-domain Technologies from university to industries. Led by National Sun Yat -Sen University, we are comprised of 6 universities of Southern Taiwan, including KMU, NKUST, NUK, NPUST and ISU Universities. We promote the R&D outcomes of Materials technology, Smart Medicine & Healthcare, Oceanic Technology, and Agriculture technology. Except to help to accelerate cross industry innovation, we also focus on the realistic demands of the members, foresee the pioneer technology by utilizing the resources of the alliance to provide suitable solutions.

NTOU GLORIA will serve as a platform further bridging the academia and industry sectors through forming a strong alliance with resources from both sectors and assets from NTOU’s resourceful alumni and partner research institutes.
The GLORIA provides customized services to the industrial partners to meet their specific needs to grow business.
As a worldwide leading academic institute in the field of marine science and technology, the NTOU GLORIA is well known for both its research achievements and tight partnerships with the industry.

The National Taiwan University, GLORIA, Taiwan is one of the Ministry of Science and Technology subsidized bodies through the Global Research & Industry Alliance program(GLORIA). NTU GLORIA is the best one and the only one combined, cross-sector and multi-themed GLORIA.

NTU GLORIA was established as a mutual benefitting bridge between the industry and National Taiwan University. It integrates National Taiwan University’s research momentum (currently consisting of 11 colleges and 3 professional colleges, 5 international, 7 national and 46 institute level research center) and provides memberships with National Taiwan University’s cross-sector, cross-industry development technology and talent resources.

NTU GLORIA also acts as a platform that integrates the school industry related bodies, including the Center of Industrial Academic Cooperation, NTU Innovation Incubation Center, Taidah Entrepreneurship Center, Career Center – NTU Office of Student Affairs etc. As a matching window for National Taiwan University and the industry, the National Taiwan University Industry Liaison Office offers memberships with integrated industry-academia co-operation services.

With the spirit of “Practice-Oriented Education”, Taiwan Tech is acknowledged as a leading pioneer among technologically advanced universities in Taiwan. It is home to provide innovative and key technologies to the global market. Taiwan Tech GLORIA has been supporting Taiwan Tech’s research and is dedicated to integrating industry-university-government high tech ecosystem under one roof to boost beneficially bilateral and multilateral cooperation in cutting edge technology fields. Taiwan Tech GLORIA provides “One-Stop Consulting Service” to our members and customized marketing service programs based on their needs to minimize initial barriers of entry and help them to uncover new opportunities in the market. We believe that a good platform of knowledge exchange and mobilization requires more than one leaders. Therefore, it is essential to ally partnerships with both private and public sectors in upgrading the quality and increasing the influence. With the commitment of promoting collaboration between university and industry, Taiwan Tech GLORIA will continuously play a vital role and devote ourselves to meet the needs of our faculty and corporate partners to accelerate advances in technology and knowledge discovery.

The aim for National Tsing Hua Global Research and Industry Alliance (GLORIA) is to expand international academia-industry collaboration by compiling industry-university R&D capacity of NTHU and eight partner universities in five major fields, including Smart Manufacturing Industry, IoT and AI Industry, Semiconductor and IC Design Industry, Biomedical and Health-Care Industry, and Creative Arts and Lifestyles Industry. The alliance will collaborate with the NTHU R&D team on the Translational Research Project to implement technology commercialization; thus verifies the feasibility of advance technology concepts or field trials for possibilities of mass production of a matured technology. The platform of alliance serves to introduce professional talents to domestic and foreign companies in accordance with their needs (RAISE Project and long-term internship programs). The alliance is in charge of promoting technology transfer and patent licensing in collaboration with the Innovative Incubation Center and Division of Intellectual Property and Technology Licensing.

National Yang-Ming University (NYMU) was established in 1974 dedicated to medical doctor training and promoted to the first medicine-oriented comprehensive university in Taiwan since 1994. Six research arears are covered in NYMU including cancer research, brain research, preventive medicine, drug discovery, biomedical research, ageing as well as bioinformatics.
GLORIA (Global Research & Industry Alliance)-NYMU was established since 2017 to better strengthen research achievements linkage to industrial applications. GLORIA aims to integrate research achievements within NYMU to initiate industry-university cooperation following licensing and co-development opportunities globally. GLORIA also offers financial consultation assistance for NYMU spin-off startup company.

Taipei Medical University (TMU) is a collegiate academic institution with an extensive history in Taiwan.

Established in 1960, over the past half-century, TMU was able to grow under challenging circumstances without regular official budget from the government or funding from foundations. It underwent the processes to building the foundation, flourishing, expansion and transformation via innovation. Today, TMU has expanded into a world-class university with eleven colleges, 6,000 students per year, six hospitals (TMU hospital, Wan Fang Medical Center, Shuang Ho Hospital, Taipei Cancer Center, Taipei Neuroscience Institute, and TMU NingBo medical Center), and more than 40,000 alumni around the world, serving the society and humankind and also cultivating the future talents for the nation. These are TMU’s most concrete contributions and also its most important responsibility and mission.

In recent years, TMU has been honing its management while seeking breakthroughs and innovations. The University has experienced growth and progress in teaching, research, service, etc. and it has garnered unanimous recognition at home and abroad.

ACRO Biomedical was founded in June 2014, and is positioning in developing and producing biomaterial medical devices for human tissue engineering and regenerative medicine (TERM). ACRO Biomedical uses its proprietary supercritical CO₂ extraction technology to remove cells, fats and non-collagenous proteins from animal tissues and organs, while keeping the undiminished collagen scaffold as the biomaterials for high-end medical devices in the medical regenerative field of wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular and neural surgery, etc.

APrevent Medical Inc. has offices in Taiwan (AspirEx Medical Ltd.) and Austria (APrevent Biotech GmbH). APrevent Biotech GmbH is ISO 13485 certified for design, manufacturing, and distribution of medical devices. Our core mission is to develop innovative medical products for unmet clinical needs.

APrevent's products improve voice and communication, focusing on the development of a long-term implant system and speech conversion platform for patients with glottis insufficiency and dysarthria. We are dedicated to providing minimally invasive and innovative ENT implant and Software-as-a-Service (SaaS) technologies for voice & speech disorders, which are patient-orientated, physician friendly and improve the quality of lives around the world.

APrevent has a diverse team of clinically experienced physicians, bio-mechanical and software engineers, and researchers with deep industry expertise committed to creating vocal identities. Our developments are well IP protected; we also cooperate with international key opinion leaders. These make APrevent's product enter the market as soon as possible and create maximum market value.

Aprevent® Vocal Implant System (VOIS) An innovative adjustable implant to treat glottic insufficiency and prevent aspiration pneumonia. VOIS is now the smallest adjustable patient-specific implant to treat glottic insufficiency/unilateral vocal fold paralysis, VOIS can fine-tuning to achieve optimal outcomes and restore voice-specific spectrum profile. The total addressable market is $ 4.1B USD.

Aprevent® Intelligible Speak (AiSpeak) AiSpeak is an artificial intelligible dysarthric speech conversion platform, it helps people who suffer from dysarthria including stroke, cerebral palsy, Parkinson’s disease and brain tumor patients to communicate and operate devices by voice. The potential market is $ 9B USD.

In order to increase the database, we are collecting voice from different types of patients. We now cooperate with several medical institutions in Taiwan and Cleveland clinic in the US to develop Chinese and English dysarthria speech conversion platform. To speed up the development, we cooperate with academic institutions in Taiwan. Acknowledgments: we special thank National Chung Cheng University National Yang-Ming University.

Taiwan FDA Product Registration and Marketing Strategy Service APrevent provides medical device in-country representative and registration service and medical device market channel planning to accelerate imported product launching to market.

The platform developed by Aquavan that gives novel and effective new molecular entities for unmet medical needs. For instance, Taiwan Wild Bitter Melon which is cultivated by Taiwan government, organically planted and extracted by Aquavan, has proved its efficacy in controlling diabetes. Several molecules that were found and purified via Aquavan platform show awesome anti-cancer result in breast cancer and colon-rectal cancer. The Phase I clinical study will be conducted in Q1 2021.

More than 500 herbs information have been stored in Aquavan’s databank, based on these big data, Aquavan had already build a Target-Hit-Candidate databank which contains more than3000 targets. Aquavan expects to discover more candidate to meet the unmet medical demand in the near future.

Bioguard is a global animal health diagnostic company. We are dedicated to providing thorough animal disease diagnostic services and manufacturing various diagnostic test kits. Our name, Bioguard, it’s a combination of biology and guard. Along with our corporate motto, “Science for animal care”, it signals our company’s dedication to protecting animal health with our technologies and accurate, professional help. We provides animal disease diagnostic services and products. Our animal health diagnostic center is the first and only ISO/IEC 17025 accredited animal disease testing laboratory in Taiwan and China, which demonstrated that Bioguard meets international standards. Our canine/ feline diagnostic test kits are developed and produced by ourselves, and monitored by our research teams, including molecular biologists, clinical veterinarians and medical technologists. With our research teams, we not only support veterinarians with our diagnostic services, but also bring the frontiers of knowledge and technology to veterinarians and pet owners.

CC Biotechnology Corporation was founded in 2012. CC Bio, an ISO certified company, is specializing in Drug Delivery System. We have whole product line with R&D and Manufacture in Taiwan. CC Bio new facility of total 36,000 square-feet on one floor is capable to handle extensive production volumes from market demands. We provide up to date and continuous improvements for the overall and consistent Quality System in order to meeting all critical requirements ISO13485, FDA21 CFR820 and GMP. The products are developed by our own R&D team, and have been highly approved by our customers.

EirGenix, Inc. (Stock Code: 6589) was founded in 2012 for the purpose of acquiring the spin-off unit of cGMP biopharmaceutical pilot facility from the Development Center for Biotechnology (DCB) in Taiwan. Formosa Laboratories has been one of EirGenix’s major investors and a strategic partner since its inception. EirGenix has raised more than ~100 million US dollars since its inception. EirGenix is in the process of completing its IPO process to be listed in the TPEx.

The company operates two business units, a CDMO unit providing biopharmaceutical contract development and manufacturing services and a product unit developing high quality and affordable biosimilars to the benefits of patients around the global.

EirGenix owned 2 cGMP facilities (one mammalian, one microbial) in New Taipei City. Another commercial production facility with the scale of twelve (12) 2000 L single use bioreactor systems in Zhubei, Northern Taiwan was on stream for production on the 23rd of January, 2019. Endowed with such indispensable resources, EirGenix is capable of biopharmaceutical activities from pre-clinical research to NDA. The strategy to phase the expansion of the plant’s production is to allow it to organically grow with the company’s future needs, which will be fueled by rising domestic and foreign demand for EirGenix’s services as a contract development and manufacturing organization (CDMO), and its own proprietary drug products.

EirGenix is committed to providing client-centric products and services to ensure our customers achieve their business goals. Our dedicated team of professionals work closely with our clients to ensure that our clients receive the highest-quality products and services that are both timely and cost-effective. By striving to be a responsible and reliable service provider, we hope to build lasting and mutually-productive partnerships with our clients.

EirGenix has received numerous awards, most recently including “Asia’s Best CMO” awarded in 2018 by Biologics Manufacturing Asia (BMA) and Best BioProcessing Excellence in Taiwan Award in 2019 6th Annual Biologics Manufacturing Asia

Company Profile：
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee’s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology and derived drug products targeting specialty markets, and its first-in-class NCE programs targeting disease areas with high unmet needs.

Product / Service：
Foresee's product portfolio includes late stage and early stage programs such as FP-001, 6-month and 3-month, stable, ready-to-use versions of leuprolide mesylate injectable suspension (LMIS), for which regulatory submissions are planned in 2019; FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a Phase 2 proof-of-concept study; FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently in planning (Fanconi Anemia; mitochondrial-mediated diseases); and FP-004, a novel, subcutaneously injectable depot product in development for the treatment of opioid use disorder and pain.

GlycoNex specializes in the discovery and the development of antibody-based therapeutics. With a specific focus on glycan-directed cancer therapies, GlycoNex has established an anti-glycan antibody bank, which includes 50+ antibodies.

GlycoNex has developed a comprehensive platform for antibody development, which covers plasmid constructions, stable cell line development, analytical development and all the way to the 50L-production. Based on this platform, GlycoNex has created different types of products including innovative antibodies, biosimilars (ex. Denosumab), and Fc-fusion protein. GlycoNex is looking for opportunities to license products out or co-develop with partners.

Health Ever Bio-Tech Co., Ltd. (HEB) was established to focus on the research and development of innovative botanical drugs backed with scientific and medical evidences for today’s great unmet medical needs. With in-house ISO/IEC 17025 certified laboratory and PIC/S GMP manufacturing facility, HEB has been actively involved in the preclinical and clinical development of botanical new drugs that have been verified effective and safe on animal, cellular and human studies. HEB has built a network of domestic and international scientific advisors and consultants who are top-notch in the industry to maximize the success and quality of our pipeline. HEB endeavors to provide botanical new drugs of the best quality and makes strenuous efforts to improve the health of our compatriots.

Established in 2013, Leadgene Biomedical, Inc. is a company specializing in immunotechnology and especially in monoclonal antibody and protein development. We focus on the development of monoclonal antibody and application platforms, including IVD kit development and antibody drug development, as well as related reagents for both academic research and in vitro diagnostics use.

We have expanded our expertise to several fields, providing comprehensive technology from gene to protein, antibody applications, and various immunoassay platforms. In addition, we serve as a connection between the upstream and downstream chain groups all over the world through our technology and industrial value.

Based on a high level of expertise and exclusive technologies, Leadgene provides the best quality products to our customers and offers a wide range of customized service according to clients’ specification.

We are devoted to delivering the highest quality products and premium services that meet the needs and demands of our customers.

Lite-Med Inc., founded in 1991, is one of the best Medical Equipment Manufacturer in Taiwan. As a technical oriented company, we are specialized in the technology of Shock Wave, Image Processing, Medical UI design etc. We successfully integrated Computer, Precision Machinery and Semiconductor Automatic Control to achieve the most advanced ESWL (Extracorporeal Shock Wave Lithotripter) all over the world. ESWL is a non-invasive machine esp. for the treatment of Kidney & Ureter Stone. You are mostly welcomed to find the feature of our ESWL from following link.
https://www.youtube.com/watch?v=QC31qd4Uluc
Our ESWL has been certified by GMP, ISO13485, CE, FDA and TFDA etc. We are looking for the professional party from different country to be our distributor!

Mycenax as a bio-CMC based company, we are focusing on:
1) CDMO service
2) biological drug development including new biologics entities and biosimilars
For CDMO services, we offer a one-stop shop and fully-integrated solution to serve various needs. Our facilities are PIC/S GMP certified and registered in USFDA and MHLW.
For biological drug development, we have more than 10 pipelines mainly covered the field of oncology and autoimmune disease. The pipelines below are currently open for partnering.
Pipelines (New biologics entities):
‧Launched: TuNEX (anti-TNF medication for treatment of rheumatoid arthritis)
‧Clinical phase: TuNEX (anti-TNF medication for treatment of ankylosing spondylitis)
‧Early stage R&D: MBI-002 (immune checkpoint agonist for the treatment of solid tumors) Pipelines (biosimilars):
‧Clinical phase: LusiNEX (tocilizumab)
‧Pre-IND: AiNEX (bevacizumab), GranNEX (filgrastim), Omalizumab

The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH). The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.

The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services. MOHW's mandate also includes biotechnology R & D, international health cooperation, and diverse other areas affecting public health and well-being far beyond Taiwan. The MOHW will continue to pursue the goals of effective teamwork and coordinated planning for health and welfare services that meet changed needs of Taiwan citizens.

PharmaEssentia Corp. is a fully integrated global biopharmaceutical company headquartered in Taipei, Taiwan. It was established by a group of highly accomplished scientists from leading pharmaceutical companies, and led by seasoned executives with 100+ years of experience at biotechnology and regulatory agencies. The company aims to deliver efficacious, safe, and cost-effective therapeutic products to treat human disease, while bringing long lasting value to stakeholders.

Ropeginterferon alfa-2b is a novel, mono-pegylated proline interferon alfa-2b invented by PharmaEssentia and manufactured at its own biologics facility in Taichung, Taiwan. The biologics facility had been certified by Taiwan Food and Drug Administration and European Medicines Agency, and is also designed and operated to be compliant with US FDA requirements.

impson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used fordietary supplements & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag. New products launched in 2019: 1>. Potent anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; 2>. World first high purity (chitobiose+chitotriose >90%) oligo chitosan for weight, diabetes and triglyceride control; 3.> Hydrolyzed Fucoidan for immune & glucose control. SBC has won numerous awards with 52 patents issued.

The Ministry of Health and Welfare of the Republic of China (MOHW) is the Executive Yuan ministry responsible and the highest authority for the administration of the public health system, social welfare, affordable and universal health care, hospitals, pharmaceutical, immunization programs, disease prevention, supervision and coordination of local health agencies in Taiwan. The MOHW was originally established on 17 March 1971 as the Department of Health (DOH). The department was upgraded to Ministry of Health and Welfare on 23 July 2013 with the addition from the agencies in the Ministry of the Interior responsible for social welfare following restructuring of the Executive Yuan. The mission of MOHW is to promote the health and well-being of all Taiwan citizens.

The MOHW's diversified responsibilities include health policy planning and promotion, prevention and control of disease, food safety, drug management, social insurance and welfare, relief and protective services. MOHW's mandate also includes biotechnology R & D, international health cooperation, and diverse other areas affecting public health and well-being far beyond Taiwan. The MOHW will continue to pursue the goals of effective teamwork and coordinated planning for health and welfare services that meet changed needs of Taiwan citizens.

TaiHao Medical Inc. is an artificial intelligence (AI) company founded in 2013, Taipei, Taiwan. The image processing methodology with AI is evaluated to be helpful in assisting physicians in breast cancer detection and diagnosis. The available products include "BR-Viewer" and "BR-FHUS Smart System" focusing on breast screening to meet the upcoming requirements. Either for automated breast ultrasound or hand-held ultrasound images, the corresponding computer-aided system is ready. We aim at being the leader of medical software with whole body health care in the world.

We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs).

Our technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the US. We have used our proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need.

TTY Biopharm is a Taiwan based pharmaceutical company advanced in long-acting special formulation drugs development, focus on Liposomal formulation and Microsphere platform and international marketing.

Not only technology, TTY also developed Oncology and anti-critical Infection portfolio in Taiwan which is the number 1 domestic pharma in hospital sector and major South-East Asian countries. To support commercial, TTY has two major manufacture sites. One is a dedicated cytotoxic plant and certified to meet US FDA, EMA and PMDA inspection standard for Oncology products. Another one is a dedicated non-cytotoxic plant and certified to meet PMDA inspection standard for non-cytotoxic products.

UnicoCell BioMed is a biomedical company in Taiwan and focus on stem cell drug development and cell therapy technology development. Our capabilities include our own R&D team, PIC/S GMP cell manufacturing facility, and sales & marketing team. Unique bioreactor based manufacturing technology allows us to mass produce high quality cell therapy product and high purity stem cell secretions. The main products and services are as follows:
1. ”ELIXCYTE® ”, The new stem cell drug, is an allogeneic adipose stem cell product for the treatment of knee osteoarthritis and chronic kidney disease and is currently in the phase I/II clinical trials (phase I/II, US-FDA, TFDA IND ).
2. "Unico-Vial” –Old school, new design/patented cyrotube & Drug container , is an ideal biopreservation container system for cell therapy product, providing for closure integrity, sample stability and ready access to clinical use
3. “Perfectin® ” –Industrial production of Adipose stem cell derived factors and exosomes for cosmetic & medicinal use.
4. Licensed autologous cell therapy services.